ROFI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 315
EU - Europa 84
AS - Asia 21
SA - Sud America 5
AF - Africa 4
Totale 429
Nazione #
US - Stati Uniti d'America 311
IT - Italia 51
FR - Francia 16
VN - Vietnam 8
DE - Germania 6
CL - Cile 5
CN - Cina 5
AT - Austria 4
CA - Canada 4
IN - India 4
SG - Singapore 4
ZA - Sudafrica 4
RU - Federazione Russa 3
UA - Ucraina 2
FI - Finlandia 1
HU - Ungheria 1
Totale 429
Città #
Fairfield 36
Buffalo 27
Santa Cruz 26
Serra 24
Seattle 23
Houston 22
Woodbridge 22
Ashburn 17
Wilmington 14
Pisa 12
Cambridge 9
Dong Ket 6
Las Vegas 6
Phoenix 5
Chicago 4
Des Moines 4
Muizenberg 4
Turin 4
Ann Arbor 3
Clearwater 3
Dallas 3
Los Angeles 3
Basking Ridge 2
Beijing 2
Boardman 2
Florence 2
Paris 2
Provo 2
Pune 2
Riva 2
San Diego 2
San Francisco 2
Stuttgart 2
Toronto 2
Vienna 2
Wuhan 2
Bengaluru 1
Bloomfield 1
Büdelsdorf 1
Cheyenne 1
Dulles 1
Gyor 1
Helsinki 1
Henderson 1
Herndon 1
Jacksonville 1
Lake Forest 1
Landshut 1
Milan 1
New Orleans 1
New York 1
Ottawa 1
Portland 1
San Jose 1
Shanghai 1
University Park 1
Valeggio sul Mincio 1
Voronezh 1
Yakutsk 1
Totale 328
Nome #
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment, file e0d6c92a-650f-fcf8-e053-d805fe0aa794 124
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer, file e0d6c929-bf6d-fcf8-e053-d805fe0aa794 115
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment, file e0d6c92a-0b5b-fcf8-e053-d805fe0aa794 93
Implications of KRAS mutations in acquired resistance to treatment in NSCLC, file e0d6c929-b8bf-fcf8-e053-d805fe0aa794 77
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers, file e0d6c92f-b519-fcf8-e053-d805fe0aa794 6
null, file e0d6c929-b0d0-fcf8-e053-d805fe0aa794 4
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response, file e0d6c92b-0ec5-fcf8-e053-d805fe0aa794 4
null, file e0d6c92b-578e-fcf8-e053-d805fe0aa794 3
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC, file e0d6c92d-1d69-fcf8-e053-d805fe0aa794 3
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report, file e0d6c92d-2e09-fcf8-e053-d805fe0aa794 3
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?, file e0d6c929-a235-fcf8-e053-d805fe0aa794 2
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7, file e0d6c929-c55e-fcf8-e053-d805fe0aa794 2
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial, file e0d6c92b-4fcb-fcf8-e053-d805fe0aa794 2
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer, file e0d6c92b-6b0a-fcf8-e053-d805fe0aa794 2
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients, file e0d6c92d-aaf3-fcf8-e053-d805fe0aa794 2
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel, file e0d6c931-a601-fcf8-e053-d805fe0aa794 2
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment, file e0d6c929-e088-fcf8-e053-d805fe0aa794 1
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells, file e0d6c92a-1d74-fcf8-e053-d805fe0aa794 1
Clinical pharmacology of intravitreal anti-VEGF drugs, file e0d6c92a-2dab-fcf8-e053-d805fe0aa794 1
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance, file e0d6c92a-ac58-fcf8-e053-d805fe0aa794 1
Totale 448
Categoria #
all - tutte 970
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 970


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201920 0 0 0 0 0 0 0 0 0 3 8 9
2019/2020131 7 8 2 5 17 15 10 23 16 10 9 9
2020/202174 5 8 1 5 5 7 5 5 9 8 8 8
2021/202286 7 3 3 4 11 3 4 6 3 2 30 10
2022/202372 1 4 24 16 4 9 2 1 1 2 7 1
2023/202454 4 4 9 3 8 7 4 5 1 9 0 0
Totale 448